Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany
{{output}}
Background: The decision matrix applied by the Institute for Quality and Efficiency in Health Care (IQWiG) for the quantification of added benefit within the early benefit assessment of new pharmaceuticals in Germany with its nin... ...
